[A20-111] Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V
Last updated 04.06.2021
Commission awarded on 02.12.2020 by the Federal Joint Committee (G-BA).
Adult patients with advanced (FIGO stages III and V) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status.
Patients without detectable tumour after primary surgery and patients without detectable tumour/with complete response following chemotherapy: indication of considerable added benefit.
Patients without detectable tumour after interval surgery and patients with partial response: indication of lesser benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.